Abcam, ab250998, Anti-ENO1 + ENO2 + ENO3 antibody [EPR18422] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal ENO1 antibody. Carrier free. Suitable for WB and reacts with Recombinant full length protein - Human, Mouse, Rat, Human samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR18422,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Mouse, Rat, Human,
Applications:WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab250998 is the carrier-free version of
ab189892
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
ENO1 ENO2 and ENO3 also known as alpha gamma and beta enolase are isoenzymes involved in the glycolytic pathway. Each enolase isoenzyme offers specific mechanical functions in this energy-producing process. ENO1 has an approximate mass of 47 kDa and is widely expressed in most tissues. ENO2 similar in size is primarily found in neural and neuroendocrine tissues. ENO3 also roughly 47 kDa predominantly expresses in muscle tissue. These proteins catalyze the reversible conversion of 2-phosphoglycerate to phosphoenolpyruvate playing an important role in glycolysis.
Biological function summary
The enolase family of isoenzymes acts as multifunctional catalysts and has roles beyond glycolysis. ENO1 serves as a plasminogen receptor on cell surfaces assisting in tissue remodeling and immune response. ENO2 often referred to as neuron-specific enolase (NSE) functions importantly in neural development and tumor cell metabolism. ENO3 or muscle-specific enolase contributes to muscle metabolism and energy turnover. While these proteins individually carry out essential tasks they also form a complex that facilitates efficient energy production and cellular regulation.
Pathways
The enolase enzymes integrate in the glycolytic and gluconeogenesis pathways central to energy metabolism. Glycolysis involves other key proteins like hexokinase and phosphofructokinase cooperating for glucose breakdown and energy release. In gluconeogenesis the enolases help generate glucose from non-carbohydrate sources important during fasting or intense exercise. Their activity along with related proteins impacts the efficiency and regulation of energy metabolism pathways.
Enolase dysregulation associates with conditions like cancer and neuromuscular diseases. Elevated ENO2 levels often serve as a biomarker for neuroendocrine tumors and a target for cancer therapies. ENO3 mutations link to muscle metabolic disorders including glycogen storage diseases. ENO1 interaction with proteins such as plasminogen can influence cancer cell invasion and metastasis highlighting its relevance in disease progression and potential therapeutic interventions.